Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) — Cash Flow Reinvestment Rate

Latest as of September 2025: 97.08x

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has a Cash Flow Reinvestment Rate of 97.08x as of September 2025, reinvesting CN¥52.78 Million (capex CN¥52.78 Million ) from operating cash flow of CN¥543.69K. Explore cash flow conversion of Suzhou Zelgen Biopharmaceuticals Co Ltd to assess how effectively this company generates cash.

Reinvestment Rate

97.08x

(Capex + Investments) / Operating CF

Total Reinvested

CN¥52.78 Million

Capex + Investments

Operating Cash Flow

CN¥543.69K

CNY

Capital Expenditures

CN¥52.78 Million

CNY

Suzhou Zelgen Biopharmaceuticals Co Ltd Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for Suzhou Zelgen Biopharmaceuticals Co Ltd across 1 annual periods. Explore debt repayment capacity of Suzhou Zelgen Biopharmaceuticals Co Ltd to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Suzhou Zelgen Biopharmaceuticals Co Ltd (2024–2024)

Year-by-year capital reinvestment analysis for Suzhou Zelgen Biopharmaceuticals Co Ltd. For live market cap and broader valuation context, see 688266 market cap.

Year	Reinvestment Rate	Total Reinvested (CNY)	Operating CF	Capex	YoY Change
2024	48.30x	CN¥1.85 Billion	CN¥38.20 Million	CN¥95.69 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow